Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Innoviva Inc (INVA)  
$16.08 0.07 (0.43%) as of 4:30 Wed 5/22


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 101,390,000
Market Cap: 1.63(B)
Last Volume: 668,805 Avg Vol: 666,964
52 Week Range: $12.32 - $16.78
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Innoviva is a company with a portfolio of royalties and other healthcare assets. Co.'s royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY® ELLIPTA®. Co. is entitled to royalty payments made by GSK under its agreements that assigned to Theravance Respiratory Company, LLC (TRC), including TRELEGY® ELLIPTA® and any other product or combination of products that may be discovered or developed in the future under the Long-Acting Beta2 Agonist Collaboration Agreement and the Strategic Alliance Agreement with GSK, which have been assigned to TRC other than RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 215,000 664,000
Total Buy Value $0 $0 $2,804,388 $8,468,005
Total People Bought 0 0 1 2
Total Buy Transactions 0 0 5 12
Total Shares Sold 0 0 10,994 10,994
Total Sell Value $0 $0 $153,810 $153,810
Total People Sold 0 0 1 1
Total Sell Transactions 0 0 1 1
End Date 2024-02-22 2023-11-21 2023-05-23 2022-05-23

   
Records found: 704
  Page 13 of 29  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Pasqualone Frank Sr. Vice President, Operations   •       –      –    2014-01-23 4 A $0.00 $0 D/D 20,000 20,000     -
   Lee Junning Sr. VP, Technical Operations   •       –      –    2014-01-23 4 A $0.00 $0 D/D 11,000 152,141     -
   Lee Junning Sr. VP, Technical OperationsOf   •       –      –    2014-01-06 3 IO $0.00 $0 D/D 0 141,141     -
   Shafer Bradford J Sr VP, Gen. Counsel, Secretary   •       –      –    2013-11-20 4 D $36.40 $166,312 D/D (4,569) 300,074     -
   Winningham Rick E Chief Executive Officer   •       •      –    2013-11-20 4 D $36.40 $365,674 D/D (10,046) 680,060     -
   Mammen Mathai SVP, Research & Early Clin Dev   •       –      –    2013-11-20 4 D $36.40 $166,312 D/D (4,569) 222,073     -
   Aguiar Michael W Sr VP, Chief Financial Officer   •       –      –    2013-11-20 4 D $36.40 $166,312 D/D (4,569) 133,777     -
   Glaxosmithkline Plc 10% Owner   –       –       •   2013-10-29 4 B $37.66 $4,913,613 I/I 130,473 29,916,073 1.5     -
   Jonker Jeffrey David Senior VP, Corp. & Bus. Dev.   •       –      –    2013-10-22 4 A $0.00 $0 D/D 15,000 15,000     -
   Mammen Mathai SVP, Research & Early Clin Dev   •       –      –    2013-10-03 5 GD $0.00 $0 D/D 450 221,623     -
   Winningham Rick E Chief Executive Officer   •       •      –    2013-09-12 4 AS $40.03 $894,791 D/D (22,353) 690,106     -
   Mammen Mathai SVP, Research & Early Clin Dev   •       –      –    2013-08-21 4 OE $16.00 $300,000 D/D 18,750 226,642     -
   Shafer Bradford J Sr VP, Gen. Counsel, Secretary   •       –      –    2013-08-20 4 D $35.89 $135,413 D/D (3,773) 304,643     -
   Aguiar Michael W Sr VP, Chief Financial Officer   •       –      –    2013-08-20 4 D $35.89 $164,017 D/D (4,570) 138,346     -
   Winningham Rick E Chief Executive Officer   •       •      –    2013-08-20 4 D $35.89 $360,551 D/D (10,046) 712,459     -
   Mammen Mathai SVP, Research & Early Clin Dev   •       –      –    2013-08-20 4 D $35.89 $136,849 D/D (3,813) 207,892     -
   Malkiel Burton G Director   –       •      –    2013-08-08 5 GD $0.00 $0 D/D 1,000 35,000     -
   Mammen Mathai SVP, Research & Early Clin Dev   •       –      –    2013-07-30 4 AS $36.51 $255,570 D/D (7,000) 211,705     -
   Glaxosmithkline Plc 10% Owner   –       –       •   2013-07-30 4 B $111,851,000.00 $3 I/I 3,064,407 29,785,600 1.5     -
   Shafer Bradford J Sr VP, Gen. Counsel, Secretary   •       –      –    2013-07-24 4 A $0.00 $0 D/D 5,000 308,416     -
   Winningham Rick E Chief Executive Officer   •       •      –    2013-07-24 4 A $0.00 $0 D/D 11,000 722,505     -
   Mammen Mathai SVP, Research & Early Clin Dev   •       –      –    2013-07-24 4 A $0.00 $0 D/D 5,000 218,705     -
   Blum Leonard M Sr VP, Chief Comm. Officer   •       –      –    2013-07-24 4 A $0.00 $0 D/D 5,000 291,094     -
   Aguiar Michael W Sr VP, Chief Financial Officer   •       –      –    2013-07-24 4 A $0.00 $0 D/D 5,000 142,916     -
   Shafer Bradford J Sr VP, Gen. Counsel, Secretary   •       –      –    2013-06-07 4 S $35.04 $1,087,572 D/D (31,038) 303,416     -
  704 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 13 of 29
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us